Candel Therapeutics, Inc.
corporate_fare Company Profile
Candel Therapeutics, Inc. (NASDAQ:CADL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CADL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CADL spans 8-K, 10-Q, DEF 14A, SCHEDULE 13D/A.
Recent high-impact activity:
- Shares Sink 38% After-Hours as Candel Updates Application Timing
- Candel Q3 Loss Widens to $21.9M; Prostate Cancer BLA Slips to Mid-2027
- Q3 Loss Nearly Doubles to $21.9M as R&D Spend Jumps; Cash Lasts Into Q2 2028
- Candel's Aglatimagene Shows 24.5-Month Survival in NSCLC Patients Failing Immunotherapy
- Candel's Prostate Cancer Therapy Shows Durable Immune Remodeling Two Years Post-Treatment
Financial Snapshot
Short Interest & Short Volume
13.31 days to coverFINRA reported short interest of 13,087,782 shares in CADL as of the October 30, 2026 settlement, a 2.5% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 20, 2026, 50.6% of CADL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CADL, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.
New $50M ATM Program Established · Prior $50M Facility Fully Exhausted
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →